कंपनी का अवलोकन
Exact Sciences Corporation operates within the healthcare sector, specifically focusing on the diagnostics and research industry by providing cancer screening and diagnostic test products globally. The company's primary offering is Cologuard, a non-invasive stool-based DNA screening test designed to detect biomarkers associated with colorectal cancer and pre-cancer, alongside the Cologuard Plus Test. As of the latest data, the entity commands a market capitalization of $20.03B and generates annual revenue of $3.25B, while employing approximately 7,100 individuals worldwide. This substantial market capitalization and significant revenue stream indicate that Exact Sciences holds a prominent position in the colorectal cancer screening market, reflecting its established footprint and the critical demand for its diagnostic solutions. The scale of operations, supported by a workforce of 7,100 employees, suggests a robust infrastructure capable of supporting extensive distribution networks both in the United States and internationally.
वित्तीय स्वास्थ्य
The financial performance of the company over the trailing twelve months shows a revenue of $3.25B against a net income of -$207,948,992, revealing a significant divergence between top-line growth and profitability. Despite generating $71.46M in EBITDA, the negative net income highlights a cost structure where operating expenses likely exceed gross profits, resulting in a loss for the reporting period. The company demonstrates strong financial flexibility with free cash flow of $281.87M, indicating that operational cash generation is sufficient to cover capital expenditures and potentially fund R&D or debt obligations without relying on external financing. However, the liquidity profile is complicated by a total cash balance of $964.71M sitting against total debt of $2.53B, which points to a leveraged balance sheet rather than a conservative one. This leverage is quantified by a debt-to-equity ratio of 105.57, suggesting that the company finances a significant portion of its operations through borrowed funds relative to shareholder equity. Profitability metrics further illustrate this challenge, with a gross margin of 69.7% indicating strong pricing power or cost control on sales, yet offset by an operating margin of -9.3% and a profit margin of -6.4%. Short-term liquidity appears manageable given a current ratio of 2.43, which implies the company possesses more than twice the current assets necessary to meet its short-term liabilities. Return on equity stands at -8.7% and return on assets at -1.6%, metrics that reveal management has yet to generate positive returns on the capital invested by shareholders or utilized in asset creation during this specific period.
मूल्यांकन आकलन
Valuation metrics present a mixed picture, with the P/E ratio (TTM) listed as N/A due to current earnings losses, while the forward P/E stands at 55.22, implying high expectations for future earnings recovery or growth. The price-to-book ratio is recorded at 8.34, suggesting that the market values the company at a significant premium over its net asset value, potentially reflecting intangible assets or future growth potential rather than current book value. Alternative valuation measures include a price-to-sales ratio of 6.17 and an EV/EBITDA of 302.23, which indicate that investors are pricing the stock based on revenue and cash flow generation rather than current profitability. The stock's price volatility relative to the broader market is indicated by a beta of 1.44, meaning the share price tends to fluctuate more aggressively than the general market index. Regarding trading ranges, the 52-week high is $104.98 and the 52-week low is $38.81, placing the current valuation context within a wide historical band where the stock has experienced substantial price swings.
Growth & Income
Revenue growth over the year-on-year period stands at 23.1%, demonstrating a robust expansion in sales volume or market penetration, whereas earnings growth is N/A due to the lack of positive net income in the trailing twelve months. The absence of positive earnings growth compared to revenue growth implies that the company is prioritizing market expansion and product adoption over immediate profit optimization, a common strategy in the early or growth phases of a diagnostic business model. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company retains all its earnings, reinvesting them into research, development, and operational scaling rather than distributing cash to shareholders. The overall growth and income profile characterizes Exact Sciences as a growth-oriented entity that relies on capital appreciation and revenue expansion rather than dividend income for investor returns.